BAYER HLTHCARE Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BAYER HLTHCARE, and what generic alternatives to BAYER HLTHCARE drugs are available?
BAYER HLTHCARE has fifty-six approved drugs.
There are thirty-seven US patents protecting BAYER HLTHCARE drugs.
There are eight hundred and five patent family members on BAYER HLTHCARE drugs in fifty-eight countries and one hundred and forty-seven supplementary protection certificates in twenty countries.
Summary for BAYER HLTHCARE
International Patents: | 805 |
US Patents: | 37 |
Tradenames: | 57 |
Ingredients: | 37 |
NDAs: | 56 |
Drugs and US Patents for BAYER HLTHCARE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bayer Hlthcare | LEVLITE | ethinyl estradiol; levonorgestrel | TABLET;ORAL-28 | 020860-002 | Jul 13, 1998 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Bayer Hlthcare | VITRAKVI | larotrectinib sulfate | CAPSULE;ORAL | 210861-001 | Nov 26, 2018 | RX | Yes | No | 8,513,263 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Bayer Hlthcare | ULTRAVIST 150 | iopromide | INJECTABLE;INJECTION | 020220-004 | May 10, 1995 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Bayer Hlthcare | ADEMPAS | riociguat | TABLET;ORAL | 204819-002 | Oct 8, 2013 | AB | RX | Yes | No | 11,203,593 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |
Bayer Hlthcare | CIPRO | ciprofloxacin hydrochloride | TABLET;ORAL | 019537-003 | Oct 22, 1987 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Bayer Hlthcare | LEVITRA | vardenafil hydrochloride | TABLET;ORAL | 021400-004 | Aug 19, 2003 | DISCN | Yes | No | 8,273,876 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Bayer Hlthcare | ADEMPAS | riociguat | TABLET;ORAL | 204819-001 | Oct 8, 2013 | AB | RX | Yes | No | 7,173,037 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for BAYER HLTHCARE
Paragraph IV (Patent) Challenges for BAYER HLTHCARE drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 20 mg | ➤ Subscribe | 2009-03-05 |
➤ Subscribe | Tablets | 2.5 mg | ➤ Subscribe | 2009-09-04 |
➤ Subscribe | Tablets | 200 mg | ➤ Subscribe | 2014-02-28 |
➤ Subscribe | Tablets | 3 mg/0.03 mg/0.451 mg and 0.451 mg | ➤ Subscribe | 2012-09-28 |
➤ Subscribe | Transdermal System | 0.05 mg/day and 0.1 mg/day | ➤ Subscribe | 2005-09-12 |
➤ Subscribe | Tablets | 3 mg/0.02 mg | ➤ Subscribe | 2006-09-29 |
➤ Subscribe | Injection | 1.6 mg/mL | ➤ Subscribe | 2014-02-07 |
➤ Subscribe | Tablets | 0.5 mg, 1 mg,1.5 mg, 2 mg and2.5 mg | ➤ Subscribe | 2017-10-10 |
➤ Subscribe | Tablets | 0.25 mg/0.5 mg | ➤ Subscribe | 2015-01-08 |
➤ Subscribe | Tablets | 3 mg/0.02 mg/0.451 mg and 0.451 mg | ➤ Subscribe | 2012-11-13 |
➤ Subscribe | Tablets | 5 mg ad 10 mg | ➤ Subscribe | 2009-07-10 |
➤ Subscribe | Tablets | 3 mg; 2 mg/2 mg; 2 mg/3 mg; 1 mg | ➤ Subscribe | 2010-10-22 |
➤ Subscribe | Tablets | 25 mg, 50 mg and 100 mg | ➤ Subscribe | 2005-03-22 |
➤ Subscribe | Tablets | 40 mg | ➤ Subscribe | 2016-09-27 |
➤ Subscribe | Oral Suspension | 250 mg/5 mL and 500 mg/ 5 mL | ➤ Subscribe | 2009-10-16 |
➤ Subscribe | Tablets | 3 mg/0.03 mg | ➤ Subscribe | 2005-01-07 |
➤ Subscribe | Orally Disintegrating Tablets | 10 mg | ➤ Subscribe | 2011-12-22 |
➤ Subscribe | Tablets | 0.5 mg/1 mg | ➤ Subscribe | 2007-12-26 |
➤ Subscribe | Tablets | 3 mg/0.02 mg/0.451 mg and 0.451 mg | ➤ Subscribe | 2011-11-21 |
International Patents for BAYER HLTHCARE Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Slovenia | 2725028 | ⤷ Try a Trial |
Brazil | PI0305559 | ⤷ Try a Trial |
Australia | 2016312904 | ⤷ Try a Trial |
Cyprus | 1112460 | ⤷ Try a Trial |
South Korea | 20090061043 | ⤷ Try a Trial |
Brazil | PI0919873 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2008089389 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for BAYER HLTHCARE Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1453521 | C 2015 029 | Romania | ⤷ Try a Trial | PRODUCT NAME: LEVONORGESTREL SI ETINILESTRADIOL; NATIONAL AUTHORISATION NUMBER: RO 7793/2015/001; DATE OF NATIONAL AUTHORISATION: 20150612; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): SK. 17/0017/15-S; DATE OF FIRST AUTHORISATION IN EEA: 20150129 |
0316633 | 99C0012 | Belgium | ⤷ Try a Trial | PRODUCT NAME: AZELASTINE HYDROCHLORIDE; NAT. REGISTRATION NO/DATE: 31 IS 113 F 13 19981021; FIRST REGISTRATION: GB PL 08336/0083 19980218 |
2132206 | 122022000030 | Germany | ⤷ Try a Trial | PRODUCT NAME: FINERENON, SOWIE DESSEN SALZE, SOLVATE UND SOLVATE DER SALZE; REGISTRATION NO/DATE: EU/1/21/1616 20220216 |
1663978 | 149 13-2013 | Slovakia | ⤷ Try a Trial | FIRST REGISTRATION NO/DATE: EU/1/13/858, 20130826 |
3106463 | CA 2020 00013 | Denmark | ⤷ Try a Trial | PRODUCT NAME: LAROTRECTINIB OG/ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SAERLIGT LAROTRECTINIBSULFAT, INKLUSIV LAROTRECTINIBHYDROGENSULFAT; REG. NO/DATE: EU/1/19/1385 20190923 |
3106463 | 11/2020 | Austria | ⤷ Try a Trial | PRODUCT NAME: LAROTRECTINIB UND/ODER PHARMAZEUTISCH AKZEPTABLE SALZE DAVON, INSBESONDERE LAROTRECTINIBSULFAT, EINSCHLIESSLICH LAROTRECTINIBHYDROGENSULFAT; REGISTRATION NO/DATE: EU/1/19/1385 20190923 |
1429780 | 132013902137451 | Italy | ⤷ Try a Trial | PRODUCT NAME: CIPROFLOXACINA E DESAMETASONE(CILODEX); AUTHORISATION NUMBER(S) AND DATE(S): 48976, 20120810;041182015/M, 20121106 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.